Management of diabetic retinopathy: a systematic review.

CONTEXT Diabetic retinopathy (DR) is the leading cause of blindness in the working-aged population in the United States. There are many new interventions for DR, but evidence to support their use is uncertain. OBJECTIVE To review the best evidence for primary and secondary intervention in the management of DR, including diabetic macular edema. EVIDENCE ACQUISITION Systematic review of all English-language articles, retrieved using a keyword search of MEDLINE (1966 through May 2007), EMBASE, Cochrane Collaboration, the Association for Research in Vision and Ophthalmology database, and the National Institutes of Health Clinical Trials Database, and followed by manual searches of reference lists of selected major review articles. All English-language randomized controlled trials (RCTs) with more than 12 months of follow-up and meta-analyses were included. Delphi consensus criteria were used to identify well-conducted studies. EVIDENCE SYNTHESIS Forty-four studies (including 3 meta-analyses) met the inclusion criteria. Tight glycemic and blood pressure control reduces the incidence and progression of DR. Pan-retinal laser photocoagulation reduces the risk of moderate and severe visual loss by 50% in patients with severe nonproliferative and proliferative retinopathy. Focal laser photocoagulation reduces the risk of moderate visual loss by 50% to 70% in eyes with macular edema. Early vitrectomy improves visual recovery in patients with proliferative retinopathy and severe vitreous hemorrhage. Intravitreal injections of steroids may be considered in eyes with persistent loss of vision when conventional treatment has failed. There is insufficient evidence for the efficacy or safety of lipid-lowering therapy, medical interventions, or antivascular endothelial growth factors on the incidence or progression of DR. CONCLUSIONS Tight glycemic and blood pressure control remains the cornerstone in the primary prevention of DR. Pan-retinal and focal retinal laser photocoagulation reduces the risk of visual loss in patients with severe DR and macular edema, respectively. There is currently insufficient evidence to recommend routine use of other treatments.

[1]  B. Ray,et al.  Pituitary ablation for diabetic retinopathy. I. Results of hypophysectomy. (A ten-year evaluation). , 1968 .

[2]  J. Hardy,et al.  Selective anterior hypophysectomy in the treatment of diabetic retinopathy. A transsphenoidal microsurgical technique. , 1968, JAMA.

[3]  A. Patz,et al.  Macular edema--an overlooked complication of diabetic retinopathy. , 1973, Transactions - American Academy of Ophthalmology and Otolaryngology. American Academy of Ophthalmology and Otolaryngology.

[4]  Campbell Cj,et al.  Double-blind trial of Atromid-S in exudative diabetic retinopathy. , 1974 .

[5]  J. F. Cullen,et al.  Double-blind trial of Atromid-S in exudative diabetic retinopathy. , 1974, Transactions of the ophthalmological societies of the United Kingdom.

[6]  S. Lucas,et al.  Peripheral retinal ablation in the treatment of proliferative diabetic retinopathy: a three-year interim report of a randomised, controlled study using the argon laser. , 1977, The British journal of ophthalmology.

[7]  Curtis L. Meinert,et al.  Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. , 1978, Ophthalmology.

[8]  G. Blankenship Diabetic macular edema and argon laser photocoagulation: a prospective randomized study. , 1979, Ophthalmology.

[9]  Kroccollaborativestudygroup Blood glucose control and the evolution of diabetic retinopathy and albuminuria. A preliminary multicenter trial. , 1984, The New England journal of medicine.

[10]  K. Dahl-Jørgensen,et al.  Rapid tightening of blood glucose control leads to transient deterioration of retinopathy in insulin dependent diabetes mellitus: the Oslo study. , 1985, British medical journal.

[11]  T. Deckert,et al.  Two-Year Experience with Continuous Subcutaneous Insulin Infusion in Relation to Retinopathy and Neuropathy , 1985, Diabetes.

[12]  R. Olk Modified grid argon (blue-green) laser photocoagulation for diffuse diabetic macular edema. , 1986, Ophthalmology.

[13]  K. Dahl-Jørgensen,et al.  Effect of near normoglycaemia for two years on progression of early diabetic retinopathy, nephropathy, and neuropathy: the Oslo study. , 1986, British medical journal.

[14]  T. Olsen,et al.  Diabetic retinopathy after 3 years' treatment with continuous subcutaneous insulin infusion (CSII) , 1987, Acta ophthalmologica.

[15]  Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Early Treatment Diabetic Retinopathy Study Research Group. , 1987, Ophthalmology.

[16]  R. Rizza,et al.  Diabetic retinopathy after two years of intensified insulin treatment. Follow-up of the Kroc Collaborative Study. The Kroc Collaborative Study Group. , 1988, JAMA.

[17]  H. Ahmadieh,et al.  Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision. Clinical application of results of a randomized trial--Diabetic Retinopathy Vitrectomy Study Report 4. The Diabetic Retinopathy Vitrectomy Study Research Group. , 1988, Ophthalmology.

[18]  N. Wald,et al.  Prevention of blindness by screening for diabetic retinopathy: a quantitative assessment. , 1989, BMJ.

[19]  D L DeMets,et al.  The Wisconsin epidemiologic study of diabetic retinopathy. XI. The incidence of macular edema. , 1989, Ophthalmology.

[20]  Effect of Aspirin Alone and Aspirin Plus Dipyridamole in Early Diabetic Retinopathy: A Multicenter Randomized Controlled Clinical Trial , 1989, Diabetes.

[21]  D. DeMets,et al.  Is blood pressure a predictor of the incidence or progression of diabetic retinopathy? , 1989, Archives of internal medicine.

[22]  H. Beck-Nielsen,et al.  Effect of near normoglycemia for 5 years on progression of early diabetic retinopathy and renal involvement. , 1990, Diabetes research.

[23]  B. Klein,et al.  Effect of Pregnancy on Progression of Diabetic Retinopathy , 1990, Diabetes Care.

[24]  A randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Sorbinil Retinopathy Trial Research Group. , 1990, Archives of ophthalmology.

[25]  M. Larsen,et al.  Effect of one year continuous subcutaneous infusion of a somatostatin analogue, octreotide, on early retinopathy, metabolic control and thyroid function in Type I (insulin-dependent) diabetes mellitus. , 1990, Acta endocrinologica.

[26]  P. Reichard,et al.  Intensified conventional insulin treatment retards the microvascular complications of insulin‐dependent diabetes mellitus (IDDM): the Stockholm Diabetes Intervention Study (SDIS) after 5 years , 1991, Journal of internal medicine.

[27]  A. Kriska,et al.  The association of physical activity and diabetic complications in individuals with insulin-dependent diabetes mellitus: the Epidemiology of Diabetes Complications Study--VII. , 1991, Journal of clinical epidemiology.

[28]  Z. Gregor,et al.  Panretinal laser photocoagulation for proliferative diabetic retinopathy: the effect of laser wavelength on macular function. , 1991, The British journal of ophthalmology.

[29]  R. Klein,et al.  Association of Cigarette Smoking With Diabetic Retinopathy , 1991, Diabetes Care.

[30]  C. Pedley,et al.  Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Commentary , 1992 .

[31]  F. Ferris,et al.  Pars plana vitrectomy in the early treatment diabetic retinopathy study : ETDRS report number 17 , 1992 .

[32]  K. Dahl-Jørgensen,et al.  Blood glucose concentrations and progression of diabetic retinopathy: the seven year results of the Oslo study. , 1992, BMJ.

[33]  R. Klein,et al.  The Beaver Dam Eye Study. Retinopathy in adults with newly discovered and previously diagnosed diabetes mellitus. , 1992, Ophthalmology.

[34]  L. Benjamin,et al.  Fields, DVLC and panretinal photocoagulation , 1992, Eye.

[35]  H. Flynn,et al.  Vitrectomy in the management of diabetic eye disease. , 1992, Survey of ophthalmology.

[36]  Metaanalysis of the effects of intensive glycemic control on late complications of type I diabetes mellitus. , 1993, The Online journal of current clinical trials.

[37]  I. Ladas,et al.  Long‐term effectiveness of modified grid laser photocoagulation for diffuse diabetic macular edema , 1993, Acta ophthalmologica.

[38]  R. Klein,et al.  The association of microalbuminuria with diabetic retinopathy. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. , 1993, Ophthalmology.

[39]  P. Sönksen,et al.  Growth Hormone and Diabetes mellitus , 1993 .

[40]  T. Chalmers,et al.  Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes , 1993, The Lancet.

[41]  P. Reichard,et al.  The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. , 1993, The New England journal of medicine.

[42]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[43]  R. Klein,et al.  Is gross proteinuria a risk factor for the incidence of proliferative diabetic retinopathy? , 1993, Ophthalmology.

[44]  E. Chew,et al.  Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report no. 20. , 1995, Archives of ophthalmology.

[45]  康生 大久保,et al.  Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus : a randomized prospective 6-year study , 1995 .

[46]  R. Klein,et al.  A cohort study of the relationship of diabetic retinopathy to blood pressure. , 1995, Archives of ophthalmology.

[47]  R. Schrier,et al.  Appropriate Blood Pressure Control in NIDDM (ABCD) Trial , 1996, Diabetologia.

[48]  P. Reichard,et al.  Complications in IDDM are caused by elevated blood glucose level: The Stockholm Diabetes Intervention Study (SDIS) at 10-year follow up , 1996, Diabetologia.

[49]  B. Hoogwerf,et al.  Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. , 1996, Archives of ophthalmology.

[50]  G. Davey Smith,et al.  Risk of adverse effects of intensified treatment in insulin‐dependent diabetes mellitus: a meta‐analysis , 1997, Diabetic medicine : a journal of the British Diabetic Association.

[51]  R. Olk,et al.  Diode laser (810 nm) versus argon green (514 nm) modified grid photocoagulation for diffuse diabetic macular edema. , 1997, Ophthalmology.

[52]  R. Klein,et al.  Incidence of retinopathy and associated risk factors from time of diagnosis of insulin-dependent diabetes. , 1997, Archives of ophthalmology.

[53]  Philip D. Harvey,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 , 1998, BMJ.

[54]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[55]  H. Vet,et al.  The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. , 1998, Journal of clinical epidemiology.

[56]  A. Sjølie,et al.  Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes , 1998, The Lancet.

[57]  R. Klein,et al.  The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. , 1998, Ophthalmology.

[58]  R. Olk,et al.  Subthreshold (invisible) modified grid diode laser photocoagulation in diffuse diabetic macular edema (DDME) , 1999, Ophthalmic surgery and lasers.

[59]  H. Flynn,et al.  Vitrectomy in the management of diabetic retinopathy. , 1999, Survey of ophthalmology.

[60]  H. Taylor,et al.  Diabetic retinopathy in Victoria, Australia: the Visual Impairment Project , 2000, The British journal of ophthalmology.

[61]  M. Shichiri,et al.  Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. , 2000, Diabetes care.

[62]  Chung-May Yang SURGICAL TREATMENT FOR SEVERE DIABETIC MACULAR EDEMA WITH MASSIVE HARD EXUDATES , 2000, Retina.

[63]  D. Minckler Evidence-based ophthalmology series and content-based continuing medical education for the journal , 2000 .

[64]  Matthew D. Davis,et al.  Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. , 2000, The New England journal of medicine.

[65]  P. Hougaard,et al.  A 6-year nationwide cohort study of glycaemic control in young people with type 1 diabetes. Risk markers for the development of retinopathy, nephropathy and neuropathy. Danish Study Group of Diabetes in Childhood. , 2000, Journal of diabetes and its complications.

[66]  R. Schrier,et al.  Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. , 2000, Diabetes care.

[67]  J. Jonas,et al.  Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. , 2001, American journal of ophthalmology.

[68]  Stephen J. Aldington,et al.  UKPDS 50: Risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis , 2001, Diabetologia.

[69]  A. Kessels,et al.  Vitrectomy results in diabetic macular oedema without evident vitreomacular traction , 2001, Graefe's Archive for Clinical and Experimental Ophthalmology.

[70]  Stephen J. Aldington,et al.  Relationship between the severity of retinopathy and progression to photocoagulation in patients with Type 2 diabetes mellitus in the UKPDS (UKPDS 52) , 2001, Diabetic medicine : a journal of the British Diabetic Association.

[71]  R. Cooper-DeHoff,et al.  Efficacy of Octreotide in the Therapy of Severe Nonproliferative and Early Proliferative Diabetic Retinopathy: A Randomized Controlled Study: Response to Gehrs , 2001 .

[72]  R. Pandey,et al.  Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. , 2002, Diabetes research and clinical practice.

[73]  L. Bouter,et al.  Blood pressure, lipids, and obesity are associated with retinopathy: the hoorn study. , 2002, Diabetes care.

[74]  Matthew D. Davis,et al.  Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. , 2002, JAMA.

[75]  J. Duker,et al.  Intravitreal triamcinolone for refractory diabetic macular edema. , 2002, Ophthalmology.

[76]  P. Mehler,et al.  Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. , 2002, Kidney international.

[77]  R. Klein,et al.  The association of atherosclerosis, vascular risk factors, and retinopathy in adults with diabetes : the atherosclerosis risk in communities study. , 2002, Ophthalmology.

[78]  J. Jonas,et al.  Intravitreal injection of triamcinolone for diffuse diabetic macular edema. , 2003, Archives of ophthalmology.

[79]  T. Bek,et al.  Effects of losartan on diabetic maculopathy in type 2 diabetic patients: a randomized, double‐masked study , 2003, Journal of internal medicine.

[80]  E. Agardh,et al.  Type 1 diabetes patients with severe non-proliferative retinopathy may benefit from panretinal photocoagulation. , 2003, Acta ophthalmologica Scandinavica.

[81]  L. M. Aiello,et al.  Perspectives on diabetic retinopathy. , 2003, American journal of ophthalmology.

[82]  L. Bouter,et al.  Risk Factors for Incident Retinopathy in a Diabetic and Nondiabetic Population , 2003 .

[83]  An Intravitreous Dexamethasone Bioerodible Drug Delivery System for the Treatment of Persistent Diabetic Macular Edema , 2003 .

[84]  P. Dillinger,et al.  Vitrectomy with removal of the internal limiting membrane in chronic diabetic macular oedema , 2004, Graefe's Archive for Clinical and Experimental Ophthalmology.

[85]  Stephen J. Aldington,et al.  Methodology for retinal photography and assessment of diabetic retinopathy: the EURODIAB IDDM Complications Study , 1995, Diabetologia.

[86]  H. Keen,et al.  Photocoagulation for proliferative diabetic retinopathy: a randomised controlled clinical trial using the xenon-arc , 2004, Diabetologia.

[87]  D. Pahor Visual field loss after argon laser panretinal photocoagulation in diabetic retinopathy: full- versus mild-scatter coagulation , 2004, International Ophthalmology.

[88]  H. Parving,et al.  Protective effect of captopril on the blood-retina barrier in normotensive insulin-dependent diabetic patients with nephropathy and background retinopathy , 2004, Graefe's Archive for Clinical and Experimental Ophthalmology.

[89]  P. Mitchell,et al.  Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. , 2004, Archives of ophthalmology.

[90]  John H Fuller,et al.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.

[91]  Stephen J. Aldington,et al.  Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69. , 2004, Archives of ophthalmology.

[92]  G. Hitman,et al.  Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes , 2004, Diabetic medicine : a journal of the British Diabetic Association.

[93]  A. Erginay,et al.  Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. , 2004 .

[94]  H. Park,et al.  Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. , 2005, Korean journal of ophthalmology : KJO.

[95]  J. Jonas,et al.  Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. , 2005, Ophthalmology.

[96]  W. Mieler,et al.  Acute endophthalmitis incidence: intravitreal triamcinolone. , 2005, Archives of ophthalmology.

[97]  H. Parving,et al.  The DIabetic REtinopathy Candesartan Trials (DIRECT) Programme: baseline characteristics , 2005, Journal of the renin-angiotensin-aldosterone system : JRAAS.

[98]  Vitrectomy and Internal Limiting Membrane (ILM) Removal for Diabetic Macular Edema in Eyes With Absent Vitreo–Macular Traction Fails to Improve Visual Acuity: Results of a 12 Months Prospective Randomized Controlled Clinical Trial , 2005 .

[99]  J. Jonas,et al.  Dosage dependency of intravitreal triamcinolone acetonide as treatment for diabetic macular oedema , 2005, British Journal of Ophthalmology.

[100]  P. Aiello The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial. , 2005, Diabetes.

[101]  S. Binder,et al.  Vitrectomy for persistent diffuse diabetic macular edema. , 2005, American journal of ophthalmology.

[102]  L. Sobrin,et al.  Controversies in Intravitreal Triamcinolone Acetonide Use , 2005, International ophthalmology clinics.

[103]  Manju Patel,et al.  A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. , 2005, Ophthalmology.

[104]  M. Woodward,et al.  ADVANCE—Action in Diabetes and Vascular Disease: patient recruitment and characteristics of the study population at baseline , 2005, Diabetic medicine : a journal of the British Diabetic Association.

[105]  C. Bunce,et al.  A randomised controlled feasibility trial of vitrectomy versus laser for diabetic macular oedema , 2004, British Journal of Ophthalmology.

[106]  Grupa badawcza Pkc-Drs The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy. Initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) Multicenter Randomized Clinical Trial , 2005 .

[107]  Y. Sharma,et al.  Modified grid laser photocoagulation versus pars plana vitrectomy with internal limiting membrane removal in diabetic macular edema. , 2005, American journal of ophthalmology.

[108]  Fluocinolone Acetonide Intravitreal Implant to Treat Diabetic Macular Edema: 3–Year Results of a Multi–Center Clinical Trial , 2005 .

[109]  P Glasziou,et al.  Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial , 2005, The Lancet.

[110]  R. Spaide,et al.  INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENT OF PROLIFERATIVE DIABETIC RETINOPATHY COMPLICATED BY VITREOUS HEMORRHAGE , 2006, Retina.

[111]  Diabetic Retinopathy -- Diagnostic and Treatment Novelties , 2006 .

[112]  A. Erginay,et al.  Intravitreal triamcinolone acetonide for diffuse diabetic macular edema: phase 2 trial comparing 4 mg vs 2 mg. , 2006, American journal of ophthalmology.

[113]  J. Duker,et al.  A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. , 2006, Ophthalmology.

[114]  FOR DISEASE CONTROL AND PREVENTION , 2006 .

[115]  S. Kang,et al.  Macular grid photocoagulation after intravitreal triamcinolone acetonide for diffuse diabetic macular edema. , 2006, Archives of ophthalmology.

[116]  F. Kralinger,et al.  Long-Term Outcome after Vitrectomy for Diabetic Macular Edema , 2005, Ophthalmologica.

[117]  R. Avery,et al.  Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. , 2006, Ophthalmology.

[118]  L. Aiello,et al.  Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. , 2006, Ophthalmology.

[119]  Peter K. Kaiser,et al.  ANCHOR STUDY GROUP. RANIBIZUMAB VERSUS VERTEPORFIN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2006 .

[120]  Susan Schneider,et al.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.

[121]  R. Avery Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. , 2006, Retina.

[122]  J. Jonas,et al.  Intravitreal triamcinolone acetonide for diabetic macular edema: a prospective, randomized study. , 2006, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[123]  P. Rosenfeld Intravitreal avastin: the low cost alternative to lucentis? , 2006, American journal of ophthalmology.

[124]  R. Klein,et al.  Diabetic retinopathy in a multi-ethnic cohort in the United States. , 2006, American journal of ophthalmology.

[125]  E. Çelik,et al.  Pars Plana Vitrectomy and Removal of the Internal Limiting Membrane in Diabetic Macular Edema Unresponsive to Grid Laser Photocoagulation , 2006, European journal of ophthalmology.

[126]  J. Simpson,et al.  Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. , 2006, Ophthalmology.

[127]  N. Bressler,et al.  Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. , 2006, Ophthalmology.

[128]  S. Pocock,et al.  Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes , 2006, Diabetes Care.

[129]  S. Ozdek,et al.  Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. , 2006, American journal of ophthalmology.

[130]  A. Ertan,et al.  Visual Acuity Comparison of Vitrectomy with and without Internal Limiting Membrane Removal in the Treatment of Diabetic Macular Edema , 2006, International Ophthalmology.

[131]  Philip J Rosenfeld,et al.  Ranibizumab for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.

[132]  A. Erginay,et al.  Intravitreal triamcinolone acetonide for diffuse diabetic macular oedema: 6-month results of a prospective controlled trial. , 2006, Acta ophthalmologica Scandinavica.

[133]  M. Gillies What we don't know about avastin might hurt us. , 2006, Archives of ophthalmology.

[134]  H. Parving,et al.  An Extension of the Early Treatment Diabetic Retinopathy Study (ETDRS) System for Grading of Diabetic Macular Edema in the Astemizole Retinopathy Trial , 2006, Current eye research.

[135]  J. Jonas,et al.  Infectious and noninfectious endophthalmitis after intravitreal high-dosage triamcinolone acetonide. , 2006, American journal of ophthalmology.

[136]  Lloyd Paul Aiello,et al.  Comparison of the modified Early Treatment Diabetic Retinopathy Study and mild macular grid laser photocoagulation strategies for diabetic macular edema. , 2007, Archives of ophthalmology.

[137]  Intravitreal Triamcinolone for Refractory Diabetic Macular Edema: Two-Year Results of a Double-Masked, Placebo-Controlled, Randomized Clinical TrialGillies MC, Sutter FKP, Simpson JM, et al (Univ of Sydney, Australia) Ophthalmology 113:1533–1538, 2006§ , 2007 .

[138]  H. O. Neto,et al.  Intravitreal Bevacizumab (Avastin) in the Treatment of Proliferative Diabetic Retinopathy , 2007 .

[139]  Paul Mitchell,et al.  The eye in hypertension , 2007, The Lancet.

[140]  H. Shapiro,et al.  Ranibizumab for Neovascular Age-Related Macular Degeneration (AMD): Optical Coherence Tomography (OCT) vs. Visual Acuity (VA) Changes in PIER Study , 2008 .